Sugi Predict

Sugi Predict / Compounds / Trifluoroacetic Acid

Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL21528199

NCCCCn1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21.O=C(O)C(F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 14/20 0.55
▸ KDR P35968 11/20 0.55
▸ PIK3CD O00329 6/20 0.55
▸ PIK3CG P48736 4/20 0.55
▸ ABL1 P00519 3/20 0.55
▸ EGFR P00533 3/20 0.55
▸ HCK P08631 3/20 0.55
▸ SRC P12931 3/20 0.55
▸ PIK3CA P42336 3/20 0.55
▸ PIK3CB P42338 3/20 0.55
▸ MTOR P42345 3/20 0.55
▸ EPHB4 P54760 3/20 0.55
▸ PRKDC P78527 3/20 0.55
▸ TGFBR1 P36897 2/20 0.55
▸ BMPR1B O00238 1/20 0.55
▸ PLK4 O00444 1/20 0.55
▸ PIK3C2B O00750 1/20 0.55
▸ CASK O14936 1/20 0.55
▸ GAK O14976 1/20 0.55
▸ EPHB6 O15197 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL29669754 1.00 RET (0.55) RETKDRPIK3CDPIK3CGABL1
Trifluoroacetic Acid SCHEMBL29669791 0.93 RET (0.54) RETKDRPIK3CDPIK3CGABL1
Trifluoroacetic Acid SCHEMBL21528139 0.93 RET (0.54) RETKDRPIK3CDPIK3CGABL1
SCHEMBL21528193 0.92 RET (0.63) RETKDRPIK3CDPIK3CGABL1
SCHEMBL30404443 0.92 RET (0.63) RETKDRPIK3CDPIK3CGABL1
SCHEMBL21528202 0.87 RET (0.47) RETKDRPIK3CDPIK3CGABL1
SCHEMBL30405191 0.85 RET (0.57) RETKDRPIK3CDPIK3CGABL1
SCHEMBL20552974 0.85 RET (0.57) RETKDRPIK3CDPIK3CGABL1
SCHEMBL20552898 0.85 RET (0.57) RETKDRPIK3CDPIK3CGABL1
Trifluoroacetic Acid SCHEMBL20553551 0.84 PIK3CD (0.56) RETKDRPIK3CDPIK3CGABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166667-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2024-05-23 — — US disclosed
EP-4234031-A2 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2023-08-30 — — EP disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-11685749-B2 C26-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2023-06-27 — — US disclosed
US-20230093861-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. 2023-03-30 — — US disclosed
EP-3788049-B1 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS REVOLUTION MEDICINES INC (US) 2023-03-29 — — EP disclosed
US-20230055672-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-02-23 — — US disclosed
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2022-06-21 — — US disclosed
US-20210338824-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-11-04 — — US disclosed
US-10980889-B1 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2021-04-20 — — US disclosed
US-20210094975-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. 2021-04-01 — — US disclosed
US-20190336609-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors Revolution Medicines, Inc. 2019-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230093861-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR RET 1560/4885KDR 2961/4885PIK3CD 117/4885
US-11685749-B2 C26-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR RET 1666/4885KDR 2576/4885PIK3CD 142/4885
US-10980889-B1 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR RET 1512/4885KDR 3263/4885PIK3CD 94/4885
US-20210338824-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR RET 1512/4885KDR 3263/4885PIK3CD 94/4885
US-20190336609-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR RET 1512/4885KDR 3263/4885PIK3CD 94/4885
US-20240166667-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR RET 1666/4885KDR 2576/4885PIK3CD 142/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR RET 573/4885KDR 2661/4885PIK3CD 215/4885
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR RET 1512/4885KDR 3263/4885PIK3CD 94/4885
US-20230055672-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR RET 1512/4885KDR 3263/4885PIK3CD 94/4885
US-20210094975-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR RET 1560/4885KDR 2961/4885PIK3CD 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback